This page shows the latest Karuna Therapeutics news and features for those working in and with pharma, biotech and healthcare.
Shares rocketed following the announcement. US biotech Intra-Cellular Therapeutics has scored approval for its antipsychotic drug Caplyta for the treatment of schizophrenia, to the delight of investors. ... This includes Sage Therapeutics, Acadia
Value leaps to more than $1bn following mid-stage trial results. Just five months after its stock market debut, Karuna Therapeutics has seen its value leap to more than $1bn on ... initiate a phase 3 clinical trial of KarXT in patients with schizophrenia
Veteran researcher to head up Karuna’s antipsychotic push. Karuna's new CEO Steven Paul. ... Boston, Mass-based Karuna Pharmaceuticals is focused on targeting muscarinic cholinergic receptors for the treatment of neuropsychiatric disorders marked by
The latest from pharma, biotech and healthcare. ‘Game changing CNS’ company Karuna raises $42m. ... Karuna has all of the characteristics we look for in a game-changing CNS company.
More from news
Approximately 1 fully matching, plus 3 partially matching documents found.
Health Unlimited is a global health consultancy and communications agency built by specialists with unmatched experience, perspective and expertise. For...